Sardana, YogeshBhatti, Gurjit KaurSingh, CharanSharma, Pushpender KumarReddy, P. HemachandraBhatti, Jasvinder Singh2024-01-212024-08-142024-01-212024-08-142023-03-2824320510.1016/j.lfs.2023.121641http://10.2.3.109/handle/32116/4246Rheumatoid arthritis (RA) related autoimmunity is developed at mucosal sites due to the interplay between genetic risk factors and environmental triggers. The pre-RA phase that leads to anti-citrullinated protein antibodies, rheumatoid factor, and other autoantibodies spread in the systemic circulation may not affect articular tissue for years until a mysterious second hit triggers the localization of RA-related autoimmunity in joints. Several players in the joint microenvironment mediate the synovial innate and adaptive immunological processes, eventually leading to clinical synovitis. There still exists a gap in the early phase of RA pathogenesis, i.e., the progression of diseases from the systemic circulation to joints. The lack of better understanding of these events results in the inability to answer questions about why only after a certain point of time the disease appears in joints and why in some cases, it simply remains latent and doesn't affect joints at all. In the current review, we focused on the immunomodulatory and regenerative role of mesenchymal stem cells and associated exosomes in RA pathology. We also highlighted the age-related dysregulations in activities of mesenchymal stem cells and how that might trigger homing of systemic autoimmunity to joints. � 2023 Elsevier Inc.en-USAgingAutoimmunityJointsMesenchymal stem cellsRheumatoid arthritisReviewhttps://linkinghub.elsevier.com/retrieve/pii/S0024320523002758